

Strategic Fund Medicine List¹

Updated June 30 2021

| International Nonproprietary Name (INN) | Strength | Presentation | Indication(s) | Ref |
|--|---|----------------------------|--|-----|
| ANALGESIC MEDICINES | | | | |
| Opioid analgesics | | | | |
| Codeine | 15mg; 30mg (phosphate) | Tablet | Analgesic | |
| Morphine | 10mg/ml (sulfate or hydrochloride) in 1ml ampoule | Injection | Analgesic; Anaesthetic; Pre-operative and short procedures | |
| Morphine | 10mg/5ml (sulfate or hydrochloride) | Oral Solution | Analgesic; Palliative care | |
| Morphine | 10mg; 30mg; 60mg (sulfate) | Tablet (prolonged release) | Analgesic; Palliative care | |
| ANTI-INFECTIVE MEDICINES | | | | |
| Antibacterial | | | | |
| Amoxicillin + Clavulanic acid | 500mg + 125mg | Tablet | Antibacterial | |
| Azithromycin | 200mg/5ml | Oral Solution | Antibacterial | 2 |
| Azithromycin (<i>for Trachoma treatment</i>) | 250mg; 500mg (anhydrous) | Tablet | | |
| Benzathine benzylpenicillin | 900mg benzylpenicillin (=1.2 million IU) in 5mL vial; 1.44 g benzylpenicillin (=2.4 million IU) in 5mL vial | Powder for injection | Antibacterial; Syphilis | |
| Benzylpenicillin | 600mg (=1 million IU) (sodium or potassium salt) in vial; 3g (=5 million IU) (sodium or potassium salt) in vial | Powder for injection | Antibacterial; Syphilis | |
| Procaine benzylpenicillin | 1g (=1 million IU); 3g (= 3 million IU) in vial | Powder for injection | Antibacterial; Syphilis | |
| Clindamycin | 150mg (as hydrochloride) | Tablet | Antibacterial | |
| | 150mg (as phosphate)/ml. | Injection | | |
| | 75mg/5mL (as palmitate) | Oral liquid | | |
| Doxycycline | 100mg (hydrochloride) | Tablet; Capsule | Antibacterial; Malaria prophylaxis and treatment | |

¹ The therapeutic indications presented in this list of medicines appear as published in the 21st World Health Organization Model List of Essential Medicines published in 2019. The Strategic Fund Medicine List does not seek to replace or complement the WHO the Essential Medicine List or Member States national essential medicine lists. As a result, this list should not be utilized as reference for the development of other essential medicine lists or treatment guidelines.

² Only used as single dose treatment of genital Chlamydia Trachomatis and of trachoma.

Strategic Fund Medicine List

| | | | | |
|---|---|---|--------------------------|---|
| Sulfamethoxazole + trimethoprim | 100mg + 20mg; 400mg + 80mg; 800mg + 160mg | Tablet | Antibacterial | |
| | 200mg + 40mg/5mL | Oral liquid | | |
| | 80mg + 16mg/ml in 5ml or 10ml ampoule | Injection | | |
| Ceftazidime +avibactam | 2 g+ 0.5 g vial Powder for injection | Vial | Antibacterial | |
| Antileprosy | | | | |
| Clofazimine | 50mg; 100mg | Capsule | Leprosy | 3 |
| Dapsone | 25mg; 50mg; 100mg | Tablet | | |
| Ofloxacin | 400mg | Tablet | Leprosy (second-line) | 4 |
| Antituberculosis | | | | |
| Ethambutol | 100mg | Tablet (dispersible) | Tuberculosis | |
| Ethambutol | 100mg; 400mg (hydrochloride) | Tablet | | |
| Isoniazid | 50mg/5ml | Oral Solution | | |
| Isoniazid | 100mg | Tablet (dispersible) | | |
| Isoniazid | 300mg | Tablet | | |
| Pyrazinamide | 400mg | Tablet | | |
| Pyrazinamide | 150mg | Tablet (scored); Tablet (dispersible) | | |
| Pyrazinamide | 30mg/ml | Oral Solution | | |
| Rifabutin | 150mg | Capsule | | 5 |
| Rifampicin | 20mg/ml | Oral Solution | | |
| Rifampicin | 150mg; 300mg | Tablet; Capsule | Tuberculosis; Leprosy | 3 |
| Rifampicin + Isoniazid | 75mg + 50mg | Tablet (dispersible) | Tuberculosis | |
| Rifampicin + Isoniazid | 60mg + 30mg | Tablet (dispersible) | | |
| Rifampicin + Isoniazid | 150mg + 75mg; 300mg + 150mg; | Tablet | | |
| Rifampicin + Isoniazid + Ethambutol | 150mg + 75mg + 275mg | Tablet | | |
| Rifampicin + Isoniazid + Pyrazinamide | 75mg + 50mg + 150mg | Tablet (dispersible) | | |
| Rifampicin + Isoniazid + Pyrazinamide | 150mg + 75mg + 400mg; | Tablet | | |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | 150mg + 75mg + 400mg + 275mg | Tablet | | |
| Rifapentine | 150mg | Tablet | 6 | |

³ Medicines used in the treatment of leprosy should never be used except in combination.

⁴ To be used in combination with rifampicin as a second-line therapy for leprosy treatment.

⁵ For use in patient with HIV receiving protease inhibitors.

⁶ For treatment of latent tuberculosis infection only.

Strategic Fund Medicine List

| Antituberculosis med. 2 nd line | | | | |
|--|--|--|---|---|
| Amikacin | 1g (sulfate) in vial | Powder for Injection | Multidrug-resistant tuberculosis (MDR/TB) | |
| Bedaquiline | 100mg | Tablet | | 7 |
| Clofazimine | 50mg; 100mg | Capsule | | |
| Cycloserine | 250mg | Capsule | | |
| Cycloserine | 125mg; 250mg | Solid oral dosage form | Multidrug-resistant tuberculosis (MDR/TB) | |
| Delamanid | 50mg | Tablet | | |
| Ethionamide | 120mg | Tablet (dispersible) | | |
| Ethionamide | 125mg; 250mg | Tablet | | |
| Levofloxacin | 125mg | Tablet (dispersible) | | |
| | 250mg; 500mg; 750mg | Tablet | | |
| Linezolid | 2mg/ml | Injection for intravenous administration | | |
| | 150mg | Tablet (dispersible) | | |
| | 400mg; 600mg | Tablet | | 7 |
| Moxifloxacin | 100mg | Tablet (dispersible) | | |
| | 400mg | Tablet | | |
| Protionamide | 250mg | Tablet | | 8 |
| P-aminosalicylic acid | 4g in sachet | Granule | | |
| P-aminosalicylate sodium (PAS sodium) | 100g (60% w/w) | Granules | | |
| Streptomycin | 1g (sulfate) in vial | Powder for Injection | | |
| Terizidone | 250mg | Capsule | 9 | |
| Antifungal | | | | |
| Amphotericin B | 50mg (sodium deoxycholate or liposomal complex) in vial; 100mg (lipid complex) in vial | Powder for injection | Cryptococcal disease/Histoplasmosis | |
| Fluconazole | 50mg; 200mg | Capsule | Cryptococcal disease | |
| | 2mg/ml | Injection | | |
| | 50mg/5ml | Oral liquid | | |
| Flucytosine | 250mg; 500mg | Capsule | Cryptococcal disease | |
| | 2.5g/250ml | Infusion | | |

⁷ Procurement of this medicine through the Strategic Fund should be limited for use according to WHO recommended M/XDR-TB regimen in patients for whom there are few or no treatments available. Patients receiving this medicine should be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA).

⁸ Protionamide may be an alternative to ethionamide.

⁹ Terizidone may be an alternative to cycloserine.

Strategic Fund Medicine List

| | | | | |
|--|---|------------------------------|--|----|
| Itraconazole | 100mg | Capsule | Histoplasmosis | 10 |
| | 10mg/ml | Oral liquid | | |
| Voriconazole | 200mg | Tablet | Chronic pulmonary aspergillosis and acute invasive aspergillosis | |
| | 40mg/ml | Powder for oral liquid | | |
| | 200mg in vial | Powder for injection | | |
| ANTIVIRAL MEDICINES | | | | |
| Antiretrovirals | | | | |
| Abacavir | 60mg | Tablet (dispersible, scored) | HIV/AIDS | |
| Abacavir | 300mg | Tablet | | |
| Abacavir + Lamivudine | 120mg + 60mg | Tablet (dispersible, scored) | | |
| Abacavir + Lamivudine | 600mg + 300mg | Tablet | | |
| Atazanavir | 200mg | Capsule | | |
| Atazanavir | 300mg | Capsule | | |
| Atazanavir + Ritonavir | 300mg + 100mg | Tablet | | |
| Darunavir | 75mg; 150mg; 400mg; 600mg; 800mg | Tablet | | 11 |
| Darunavir + Ritonavir | 400mg + 50mg; 600mg + 100mg | Tablet | | |
| Dolutegravir | 10mg | Tablet (dispersible) | | |
| | 50mg | Tablet | | |
| Dolutegravir + Lamivudine + Tenofovir | 50mg + 300mg + 300mg (disoproxil fumarate equivalent to 245mg tenofovir disoproxil) | Tablet | | |
| Dolutegravir + Lamivudine + Tenofovir (alafenamide) | 50mg + 300mg + 25mg | Tablet | | 12 |
| Dolutegravir + Emtricitabine + Tenofovir (alafenamide) | 50mg + 200mg + 25mg | Tablet | | 12 |
| Efavirenz | 200mg | Tablet (scored) | | |
| Efavirenz | 600mg | Tablet | | |
| Etravirine | 100mg; 200mg | Tablet | | 13 |
| Lamivudine | 150mg | Tablet | | |
| Lamivudine | 10mg/ml | Oral Solution | | |
| Lamivudine + Zidovudine | 30mg + 60mg | Tablet (dispersible, scored) | | |

¹⁰ For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidioidomycosis, mycoses caused by *T. marneffeii* and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by *T. marneffeii* in AIDS patients.

¹¹ Age restriction > 3 years old.

¹² Tenofovir alafenamide may be considered for people with established osteoporosis and/or impaired kidney function.

¹³ Procurement of this medicine through the Strategic Fund should be limited for use as third-line therapy in treatment-experienced HIV adults who failed second-line antiretroviral therapy. It is recommended patients receiving HIV/AIDS regimens including this medicine be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA).

Strategic Fund Medicine List

| | | | | |
|---|---|------------------------------------|---|----|
| Lamivudine + Zidovudine | 150mg+300mg | Tablet | HIV/AIDS | |
| Lopinavir + Ritonavir | 100mg + 25mg; 200mg + 50mg | Tablet (heat stable) | | |
| Lopinavir + Ritonavir | 40mg + 10mg | Solid oral dosage form | | |
| Lopinavir + Ritonavir | 80mg+20mg/ml | Oral Solution | | |
| Nevirapine | 50mg | Tablet (dispersible, scored) | | |
| Nevirapine | 50mg/5ml (100ml) | Oral Solution | | |
| Ritonavir | 25mg | Tablet (heat stable) | | |
| Ritonavir | 100mg | Tablet (heat stable) | | |
| Raltegravir | 25mg; 100mg | Tablet (chewable) | | |
| Raltegravir | 100mg | Granules for oral suspension | | |
| Raltegravir | 400mg | Tablet | | |
| Tenofovir (alafenamide) | 10mg; 25mg | Tablet | | 12 |
| Tenofovir | 300mg | Tablet | | |
| Tenofovir | 200mg | Tablet | | |
| Tenofovir (alafenamide) + Emtricitabine | 10mg + 200mg 25mg + 200mg | Tablet | | 12 |
| Tenofovir + Emtricitabine | 300mg + 200mg | Tablet | | |
| Tenofovir + Emtricitabine + Efavirenz | 300mg + 200mg + 600mg | Tablet | | |
| Tenofovir + Lamivudine | 300mg + 300mg | Capsule | | |
| Tenofovir + Lamivudine + Efavirenz | 300mg + 300mg + 400mg; 300mg + 300mg + 600mg | Tablet | | |
| Zidovudine | 300mg | Tablet | | |
| Zidovudine | 50mg/5ml (100ml) | Oral Solution | | |
| Zidovudine | 10mg/ml in 20ml vial | Solution for IV Infusion Injection | | |
| Other Antivirals | | | | |
| Acyclovir | 250mg (sodium salt) in vial | Powder for Injection | Herpes Virus | |
| Acyclovir | 200mg | Tablet | | |
| Oseltamivir | 75mg (phosphate) | Capsule | Influenza Virus (in compliance with WHO treatment guidelines) | 14 |
| Oseltamivir | 12mg/ml | Powder for Oral Solution | | |
| Valganciclovir | 450mg | Tablet | Cytomegalovirus | |
| | 50mg/ml | Powder for oral solution | | |
| Prevention of HIV-related opportunistic infections medicines | | | | |
| Isoniazid + pyridoxine + sulfamethoxazole +trimethoprim | 300mg + 25mg + 800mg + 160mg | Tablet (scored) | HIV-related opportunistic infections | |

¹⁴ According to the 20th World Health Organization Model List of Essential Medicines published in March 2017, Oseltamivir is indicated for severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients.

Strategic Fund Medicine List

| Anti-hepatitis | | | | |
|---------------------------------------|--|--------------------------------------|--|----|
| Medicines for Hepatitis B | | | | |
| Entecavir | 0.05mg/ml | Oral Solution | Chronic Hepatitis B | |
| Entecavir | 0.5mg; 1mg | Tablet | | |
| Tenofovir disoproxil fumarate | 300mg | Tablet | | |
| Medicines for Hepatitis C | | | | |
| Daclatasvir | 30mg; 60mg | Tablet | Chronic Hepatitis C | 15 |
| Dasabuvir | 250mg | Tablet | | |
| Ledipasvir + Sofosbuvir | 90mg + 400mg | Tablet | | |
| Glecaprevir + Pibrentasvir | 100mg + 40mg | Tablet | | |
| Ombitasvir + Paritaprevir + Ritonavir | 12.5mg + 75mg + 50mg | Tablet | | |
| Simeprevir | 150mg | Capsule | | |
| Sofosbuvir | 400mg | Tablet | | |
| Sofosbuvir + Velpatasvir | 400mg + 100mg | Tablet | | |
| Antiprotozoal | | | | |
| Antileishmaniasis | | | | |
| Meglumine antimoniate | 1.5g/ 5ml (81mg/ml) in 5ml ampoule | Injection | Leishmaniasis | |
| Amphotericin B | 50mg (sodium deoxycholate or liposomal complex) in vial | Powder for Injection | Leishmaniasis | |
| Miltefosine | 10mg; 50mg | Tablet | | |
| Paromomycin | 750mg of paromomycin base (sulfate) | Solution for Intramuscular Injection | | |
| Pentamidine | 300mg (isethionate) | Powder for injection | Leishmaniasis | 16 |
| Anti-malarial | | | | |
| Amodiaquine | 153mg; 200mg (hydrochloride) | Tablet | Malaria treatment to be used in combination with artesunate for P. falciparum. | |
| Artemether | 80mg/ml 1ml ampoule | Oily Injection | Severe malaria | |
| Artemether + Lumefantrine | 20mg + 120mg | Tablet | Malaria treatment | |
| Artesunate | 60mg (anhydrous artesunic acid) | Injection | Severe malaria | 17 |
| Artesunate | 50mg; 200mg | Rectal Dosage Form | Severe malaria | |
| Artesunate + Mefloquine | 25mg +55mg 100mg + 220mg | Tablet | Malaria treatment | |
| Artesunate + Amodiaquine | 25mg + 67.5mg (hydrochloride); 50mg + 135mg (hydrochloride); 100mg + 270mg (hydrochloride) | Tablet | Malaria treatment | |

¹⁵ According to the 20th World Health Organization Model List of Essential Medicines published in March 2017 and based on current evidence, medicines of this class act as direct antiviral medicines and are included as essential medicines for treatment of hepatitis C virus infection. WHO guidelines recommend specific combinations therapies utilizing medicines from different classes)

¹⁶ This medicine should be used in accordance with the recommendations outlined in the Leishmaniasis in the Americas: Recommendations for the treatment (2013) guide.

¹⁷ Product may be co-packaged with 1 ampoule of 5% sodium bicarbonate solution and 1 ampoule of sodium chloride solution.

Strategic Fund Medicine List

| | | | | |
|---|---|--------------------|---|--|
| Atovaquone + Proguanil | 250mg + 100mg (hydrochloride) | Tablet (adult) | Malaria prophylaxis and treatment | |
| Atovaquone + Proguanil | 62.5+25mg (hydrochloride) | Tablet (pediatric) | | |
| Chloroquine | 50mg (phosphate or sulfate)/5ml | Oral Solution | Malaria prophylaxis and treatment | |
| Chloroquine | 100mg; 150mg (phosphate or sulfate) | Tablet | | |
| Mefloquine | 250mg (hydrochloride) | Tablet | Malaria prophylaxis; Malaria treatment to be used in combination with artesunate for P. falciparum | |
| Dihydroartemisinin + Piperaquine | 40mg + 320mg | Tablet | Malaria treatment | |
| Primaquine | 5mg; 7.5mg; 15mg (diphosphate) | Tablet | As complement to malaria treatment (for radical cure of P. vivax and P.ovale and as gametocytocide for P. falciparum) | |
| Quinine | 300mg quinine hydrochloride/ml in 2ml ampoule | Injection | Severe malaria | |
| Quinine | 300mg (quinine sulfate or bisulfate) | Tablet | Malaria treatment | |
| Sulfadoxine + Pyrimethamine | 500mg + 25mg | Tablet | Malaria treatment to be used in combination with artesunate for P. falciparum | |
| Antipneumocystosis and antitoxoplasmosis | | | | |
| Pyrimethamine | 25mg | Tablet | Antipneumocystosis; Antitoxoplasmosis | |
| Sulfamethoxazole + Trimethoprim | 100mg + 20mg; 400mg + 80mg; 800mg + 160mg | Tablet | | |
| | 200mg + 40mg/5ml | Oral liquid | | |
| | 80mg + 16mg/ml in 5ml or 10ml ampoule | Injection | | |
| Pentamidine | 200mg; 300mg | Tablet | | |
| Sulfadiazine | 500mg | Tablet | | |
| Antitrypanosomal | | | | |
| Benznidazole | 12.5mg | Tablet | American Trypanosomiasis | |
| | 50mg | Tablet (scored) | | |
| | 100mg | Tablet | | |
| Nifurtimox | 30mg | Tablet | African Trypanosomiasis (2nd stage); | |
| | 120mg | | American Trypanosomiasis | |
| Anthelmintics | | | | |
| Intestinal anthelmintics | | | | |
| Albendazole | 400mg | Tablet (chewable) | Intestinal Anthelmintic; Anti-Filarial | |
| Ivermectin | 3mg | Tablet (scored) | Strongyloidiasis Scabies | |
| Mebendazole | 500mg | Tablet (chewable) | Intestinal anthelmintic | |

Strategic Fund Medicine List

| | | | | |
|---|-------------------------------------|------------------------------------|--|----|
| Nicosamide | 500mg | Tablet (chewable) | Intestinal anthelmintic (for use when praziquantel fails) Anticestodes | |
| ECTOPARASITIC INFECTION | | | | |
| Dimeticone (medical device) | 92%, in 100 ml bottle | Oil solution | Tungiasis | 18 |
| ANTIHELMINTHIC INTESTINAL MEDICINES | | | | |
| Praziquantel | 150mg; 600mg | Tablet | Intestinal anthelmintic; | |
| Antischistosomal and Antitrematode | | | | |
| Praziquantel | 600mg | Tablet | Antischistosomal; Antitrematode; Anticestode | |
| Triclabendazole | 250mg | Tablet | Antitrichistosomal; Antitrematode | |
| Antifilarials | | | | |
| Diethylcarbamazine | 50mg; 100mg (dihydrogen citrate) | Tablet | Filariasis | |
| ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND USED IN PALLIATIVE CARE MEDICINES | | | | |
| Immunosuppressive Agents | | | | |
| Azathioprine | 100mg (sodium salt) in vial | Powder for Injection | Immunosuppressive | |
| Azathioprine | 50mg | Tablet | DMARD | |
| Cyclosporine | 25mg | Capsule | Immunosuppressive | |
| Cyclosporine | 50mg/ml in 1ml ampoule | Injection | | |
| Mycophenolate Mofetil | 250mg | Capsules | Prophylaxis of organ rejection in adult patients receiving allogeneic renal transplants | |
| | 500mg | Tablets | | |
| Tacrolimus | 0.5mg; 1,5mg | Capsules (immediate release) | Prophylaxis of organ rejection in adult patients receiving allogeneic renal or hepatic transplants | |
| Cytotoxics | | | | |
| Asparaginase | 10,000 IU in vial | Powder for Injection | Cytotoxic Agent | |
| Bleomycin | 15mg (sulfate) in vial | Powder for Injection | | |
| Calcium folinate | 3mg/ml in 10ml ampoule | Injection | Adjuvant Medicine | |
| Calcium folinate | 15mg | Tablet | | |
| Carboplatin | 150mg; 450mg | Powder for Injection | Cytotoxic and Adjuvant Medicine | |
| Chlorambucil | 2mg | Tablet | Cytotoxic Agent | |
| Cisplatin | 10mg; 50mg | Powder for Injection | Cytotoxic and Adjuvant Medicine | |
| Cyclophosphamide | 500mg in vial | Powder for Injection | Cytotoxic Agent | |
| | 25mg | Tablet | | |

¹⁸ The Dimeticone is used as a topical treatment for tungiasis. It is a combination of two low-viscosity dimeticone whose mode of action is purely physical.

Strategic Fund Medicine List

| | | | | |
|--|--|--|---|----|
| Cytarabine | 100mg in vial | Powder for Injection | Cytotoxic Agent | |
| Dacarbazine | 100mg in vial | Powder for Injection | | |
| Dactinomycin | 500µg in vial | Powder for Injection | | |
| Daunorubicin | 50mg (hydrochloride) in vial | Powder for Injection | | |
| Docetaxel | 20mg/ml | Injection | Cytotoxic and Adjuvant Medicine | |
| Doxorubicin | 10mg; 50mg (hydrochloride) in vial | Powder for Injection | Cytotoxic Agent | |
| Etoposide | 100mg | Capsule | | |
| Etoposide | 20mg/ml in 5ml ampoule | Injection | | |
| Fluorouracil | 50mg/ml in ampoule | Injection | Cytotoxic and Adjuvant Medicine | |
| Ifosfamide | 1g vial | Powder for Injection | Cytotoxic and Adjuvant Medicine | |
| Mercaptopurine | 50mg | Tablet | Cytotoxic Agent | |
| Mesna (2-mercaptoethane sulfonate sodium) | 100mg/ml in 4ml and 10ml ampoules | Injection | Adjuvant Medicine | |
| Methotrexate | 50mg (sodium salt) in vial | Powder for Injection | Cytotoxic Agent | |
| Methotrexate | 2.5mg (sodium salt) | Tablet | Cytotoxic Agent; DMARD | |
| Paclitaxel | 6mg/ml | Powder for Injection | Cytotoxic and Adjuvant Medicine | |
| Procarbazine | 50mg (hydrochloride) | Capsule | Cytotoxic Agent | |
| Tamoxifen | 10mg; 20mg (citrate) | Tablet | Hormone/Anti-Hormone | |
| Vinblastine | 10mg (sulfate) in vial | Powder for Injection | Cytotoxic Agent | |
| Vincristine | 1mg; 5mg (sulfate) in vial | Powder for Injection | | |
| Targeted therapies | | | | |
| Trastuzumab | 60mg; 150mg; 440mg in vial | Powder for injection | Early stage HER2 positive breast cancer Metastatic HER2 positive breast cancer | |
| BLOOD PRODUCTS AND PLASMA SUBSTITUTES | | | | |
| Plasma fractions for specific use | | | | |
| Human normal immunoglobulin | 16% protein solution | Injection for Intramuscular Administration | Plasma fractions for specific use | 19 |
| Human normal immunoglobulin | 5% protein solution; 10% protein solution | Injection for Intravenous Administration | | |
| Coagulation factor VIII | 500UI/vial | Powder for injection | Blood coagulation factors | |
| Coagulation factor IX | 500UI/vial; 1000UI/vial | Powder for injection | | |

¹⁹ Indicated for primary immune deficiency.

²⁰ Indicated for primary immune deficiency and Kawasaki disease.

Strategic Fund Medicine List

| IMMUNOBIOLOGICS | | | | |
|--|---|---|--|---------------|
| Sera and immunoglobulins | | | | |
| Anti-D immunoglobulin (human) | 250µg in single-dose vial | Injection | Prevention of newborn hemolytic illnesses; Rh negative populations (prophylaxis) | |
| CARDIOVASCULAR MEDICINES | | | | |
| Antihypertensives | | | | |
| Amlodipine | 5mg (maleate, mesylate or besylate) | Tablet | Antihypertensive | |
| Bisoprolol | 1.25mg; 5mg | Tablet | Antihypertensive; Antianginal; Antiarrhythmic; Medicines used in heart failure | ²¹ |
| Carvedilol | 3.125mg; 6.25mg; 12.5mg; 25mg; 50mg | Tablet | | |
| Chlorthalidone | 12.5mg; 25mg | Tablet | Hypertension in adults | |
| Hydralazine | 20mg (hydrochloride) in ampoule | Powder for Injection | Hypertension | |
| Hydralazine | 25mg; 50mg (hydrochloride) | Tablet | Hypertension | |
| Hydrochlorothiazide | 12.5mg; 25mg | Tablet | Antihypertensive; Medicines used in heart failure; Diuretics | |
| Lisinopril | 20mg; 40mg | Tablet | Hypertension | |
| Lisinopril + Amlodipine | 10mg + 5mg; 20mg + 5mg; 20mg + 10mg | Tablet | Hypertension | |
| Lisinopril + Hydrochlorothiazide | 10mg + 12.5mg; 20mg + 12.5mg; 20mg + 25mg | Tablet | Hypertension | |
| Losartan | 25mg; 50mg; 100mg | Tablets | Hypertension in adults | ²² |
| Methyldopa | 250mg | Tablet | Antihypertensive | ²³ |
| Metoprolol | 100mg | Tablet | Antihypertensive; Antianginal; Antiarrhythmic; Medicines used in heart failure | |
| Sodium nitroprusside | 50mg in ampoule | Powder for Infusion | Hypertension | |
| Surfactant (<i>exogenous pulmonary surfactant</i>) | 25mg/ml; 80mg/ml | Suspension for Intratracheal Instillation | Neonatal care | |
| Telmisartan | 40mg; 80mg | Tablet | Hypertension | |
| Telmisartan + amlodipine | 40mg + 5mg; 80mg + 5mg; 80mg + 10mg | Tablet | Hypertension | |
| Telmisartan + hydrochlorothiazide | 40mg + 12.5mg; 80mg + 12.5mg; 80mg + 25mg | Tablet | Hypertension | |

²¹ Metoprolol and carvedilol as alternatives.

²² Losartan can be used as an alternative for treatment of adults with hypertension for those patients in whom ACEi are indicated but not tolerated, specifically due to the presence of adverse events (mainly cough); including the sub-population of hypertensive patients associated with type II diabetes with proteinuria.

²³ Methyldopa is listed for use only in the management of pregnancy-induced hypertension. Its use in the treatment of essential hypertension is not recommended in view of the evidence of greater efficacy and safety of other medicines (WHO 20th EML).

Strategic Fund Medicine List

| Antiarrhythmics | | | | |
|---|---|----------------------|---|--|
| Amiodarone | 100mg; 200mg; 400mg (hydrochloride) | Tablet | Antiarrhythmic | |
| | 50mg (hydrochloride)/ml in 3-ml ampoule | Injection | | |
| Digoxin | 250 micrograms/ml in 2-ml ampoule | Injection | Antiarrhythmic Medicines used in heart failure | |
| | 62.5 micrograms; 250 micrograms | Tablet | | |
| | 50 micrograms/ml | Oral Solution | | |
| Lidocaine | 20mg (hydrochloride)/ml in 5-ml ampoule | Injection | Antiarrhythmic | |
| Verapamil | 2.5mg (hydrochloride)/ml in 2-ml ampoule | Injection | Antiarrhythmic Antianginal medicines | |
| | 40mg; 80mg (hydrochloride) | Tablet | | |
| Diuretics | | | | |
| Spironolactone | 25mg | Tablet | Diuretic | |
| Antianginal | | | | |
| Glyceryl trinitrate | 500µg | Tablet (sublingual) | Angina | |
| Antithrombotic | | | | |
| Clopidogrel | 75mg | Tablet | Prevention of atherothrombotic events in adults with non-ST segment elevation acute coronary syndrome | |
| Streptokinase | 1.5million IU in vial | Powder for Injection | Thrombosis | |
| Lipid-lowering agents | | | | |
| Simvastatin | 5mg; 10mg; 20mg; 40mg | Tablet | Lipid-Lowering Agents | |
| DIAGNOSTIC AGENTS | | | | |
| Radiocontrast media | | | | |
| Amidotrizoate | 140mg to 420mg iodine (sodium or Meglumine salt)/ml in 20ml ampoule | Injection | Radiocontrast Media | |
| HORMONES, ENDOCRINE MEDICINES | | | | |
| Contraceptives | | | | |
| Oral hormonal contraceptives | | | | |
| Ethinylestradiol + levonorgestrel | 30µg + 150µg | Tablet | Contraception | |
| Ethinylestradiol + norethisterone | 35µg + 1.0mg | Tablet | | |
| Levonorgestrel | 30µg; 750µg (pack of two); 1.5mg | Tablet | Contraception | |
| Injectable hormonal contraceptives | | | | |
| Medroxyprogesterone acetate | 150mg/ml in 1ml vial. | Depot Injection | Contraception | |
| Medroxyprogesterone acetate + estradiol cypionate | 25mg + 5mg | Injection | | |
| Norethisterone enanthate | 200mg/ml in 1ml ampoule | Oily Injection | | |

Strategic Fund Medicine List

| Insulins and other antidiabetic agents | | | | |
|---|---|----------------------|---|--|
| Insulin soluble | 40 IU/ml; 100 IU/ml in 10ml vial | Injection | Diabetes | |
| Intermediate-acting insulin | 40 IU/ml; 100 IU/ml in 10ml vial (compound insulin zinc suspension or isophane insulin) | Injection | | |
| Gliclazide* | Solid oral dosage form: (controlled-release tablets) 30mg; 60mg; 80mg * glibenclamide not suitable above 60 years. | Tablet | | |
| Metformin | 500mg (hydrochloride) | Tablet | | |
| MEDICINES AFFECTING THE BLOOD | | | | |
| Antianemia | | | | |
| Recombinant Human Erythropoietin | 2,000-5,000 UI/ml | Injection | Anemia | |
| Recombinant Human Erythropoietin | 20,000-50,000 UI/ml | Injection | | |
| Medicines affecting coagulation | | | | |
| Warfarin | 0.5mg; 1mg; 2mg; 5mg (sodium salt) | Tablet | Anticoagulant | |
| ANTIALLERGENICS AND MEDICINES USED IN ANAPHYLAXIS | | | | |
| Dexamethasone | 4mg/ml in 1ml ampoule (disodium phosphate salt) | Injection | Antiemetic; Anti-allergic /Anaphylaxis; Cytotoxic; Palliative care | |
| Dexamethasone | 2mg | Tablet | Palliative care | |
| Hydrocortisone | 100mg (sodium succinate) in vial | Powder for Injection | Anaphylaxis; Cytotoxic | |
| Vecuronium | 10mg (bromide) in vial | Powder for Injection | Muscle Relaxant | |
| OXYTOCICS AND ANTIOXYTOCICS | | | | |
| Oxytocics | | | | |
| Oxytocin | 10 UI in 1ml ampoule | Injection | Oxytocic | |
| Ergometrine | 200µg (hydrogen maleate) in 1ml ampoule | Injection | | |
| Mifepristone – Misoprostol | 200mg - 200µg | Tablets | Oxytocic | |
| Misoprostol | 200µg | Tablet | | |
| ANTICONVULSANT AND ANTIEPILEPTIC | | | | |
| Phenytoin | 25mg; 50mg; 100mg (sodium salt) | Capsule | Anticonvulsant; Antiepileptic | |
| Phenytoin | 50mg/ml (sodium salt) in 5ml vial | Injection | | |
| Phenytoin | 25mg/5ml; 30mg/5ml | Oral Solution | | |
| Phenobarbital | 50mg/ml in 5ml vial (sodium salt) | Injection | | |
| Phenobarbital | 15mg/5ml | Oral Solution | | |
| Phenobarbital | 15mg; 100mg | Tablet | | |

Strategic Fund Medicine List

| | | | | |
|---|--|-----------------------------|--|--|
| Carbamazepine | 100mg/5ml | Oral Solution | Anticonvulsant; Antiepileptic | |
| Carbamazepine | 100mg; 200mg | Tablet (chewable) | | |
| Carbamazepine | 100mg; 200mg | Tablet (scored) | | |
| Diazepam | 5mg/ml in 0.5ml; 2ml; 4ml tubes | Gel or; Rectal solution | | |
| Lorazepam | 0.5 a 2.0mg | Tablet | | |
| Magnesium sulfate | 500mg/ml in 2ml or 10ml ampoule | Injection | | |
| Valproic acid | 200mg; 500mg (sodium valproate) | Tablet (enteric- coated) | Anticonvulsant; Antiepileptic Medicine used in bipolar disorders | |
| | 100mg | Tablet (crushable) | Anticonvulsant; Antiepileptic | |
| | 200mg/5ml | Oral solution | | |
| | 100mg/ml in 4ml ampoule; 100mg/ml in 10ml ampoule | Injection | | |
| PSYCHOTHERAPEUTIC MEDICINES | | | | |
| Chlorpromazine | 25mg (hydrochloride)/ml in 2ml ampoule. | Injection | Psychotic Disorders | |
| Chlorpromazine | 25mg (hydrochloride)/5ml | Oral Solution | | |
| Chlorpromazine | 100mg (hydrochloride) | Tablet | | |
| Fluphenazine | 25mg (decanoate or enanthate) in 1ml ampoule | Injection | | |
| Haloperidol | 5mg in 1ml ampoule | Injection | | |
| Haloperidol | 2mg; 5mg | Tablet | | |
| Risperidone | 0.25mg to 6 .0mg | Tablet | | |
| Medicines used in mood disorders | | | | |
| Amitriptyline | 10mg; 25mg, 75mg (hydrochloride) | Tablet | Palliative Care; Depressive Disorders | |
| Fluoxetine | 20mg (hydrochloride) | Capsule | Palliative Care; Depressive Disorders | |
| Fluoxetine | 20mg (hydrochloride) | Tablet | | |
| Medicines used in bipolar disorders | | | | |
| Lithium carbonate | 300mg | Capsule | Bipolar Disorder | |
| Lithium carbonate | 300mg | Tablet | | |
| Medicines used for disorders due to psychoactive substance use | | | | |
| Nicotine replacement therapy (gums) | 2mg; 4mg (as polacrilex) | Gums | Tobacco cessation | |
| Nicotine replacement therapy (patch) | 5mg to 30mg/16 h; 7mg to 21mg/24h | Transdermal patch | | |
| ANTIPARKINSONISM MEDICINES | | | | |
| Biperiden | 5mg (lactate) in 1ml ampoule | Injection | Parkinson's Disease | |
| Biperiden | 2mg (hydrochloride) | Tablet | | |

Strategic Fund Medicine List

| GASTROINTESTINAL MEDICINES | | | | |
|--|---|---|--|--|
| Antiulcer | | | | |
| Omeprazole | 20mg; 40mg | Powder for oral liquid in Sachets | Antiulcer medicines | |
| | 10mg; 20mg; 40mg | Solid oral dosage form | | |
| Ranitidine | 25mg/ml (as hydrochloride) in 2-ml ampoule | Injection | | |
| | 150mg (as hydrochloride) | Tablet | | |
| | 75mg/5ml (as hydrochloride) | Oral Solution | | |
| MEDICINES ACTING ON THE RESPIRATORY TRACT | | | | |
| Antiasthmatic and medicines for chronic obstructive pulmonary disease | | | | |
| Beclomethasone | 50 micrograms (dipropionate) per dose; 100 micrograms (dipropionate) per dose (as CFC free forms) | Inhalation (aerosol) | Antiasthmatic Medicines used for chronic obstructive pulmonary disease (COPD) | |
| Ipratropium bromide | 20 micrograms/metered dose | Inhalation (aerosol) | | |
| Salbutamol | 100 micrograms (as sulfate) per dose | Inhalation (aerosol) | | |
| | 50 micrograms (as sulfate)/ml | Injection in 5-ml ampoule | | |
| | 100 micrograms (as sulfate) per dose | Metered dose inhaler (aerosol) | | |
| | 5mg (as sulfate)/ml | Respirator solution for use in nebulizers | | |
| OTHERS | | | | |
| Calcium gluconate | 100mg/ml in 10ml ampoule | Injection | Specific Use Antidotes and Other Substances Used in Poisoning; Vitamins and Minerals | |